Thyroid Eye Disease

Some patients with TED need longer to respond to teprotumumab

Patients with thyroid eye disease (TED) treated with teprotumumab may need longer than 12 weeks to see a clinically significant response, according to a study. Approximately half of the patients treated with teprotumumab experience significant improvements in proptosis at 6 weeks, according to recent trials, with a small subgroup not...